Winning is getting easier: management describes the effort needed to land each new piece of business visibly falling, wi
The model's full reasoning — Q3 2021 call → NOThe question asks whether management conveys that it has recently become easier for the company to win business than it used to be, grounded in real business won in the recent period, with the easing still in effect. Let me analyze the transcript carefully. Key points from the call: 1. The company is preparing for a potential launch of vadadustat, a drug for anemia due to CKD. 2. They discuss the market opportunity - $2 billion in the US alone. 3. They discuss their commercial preparation, including the Vifor distribution relationship for access to Fresenius dialysis providers. 4. They discuss Auryxia revenue growth - 7% increase in Q3 2021 vs Q3 2020. Now, the question is specifically about whether management conveys that winning business has become EASIER than it used to be for this company, with real recent wins demonstrating it, and the easing still in effect. Let me look for any language about: - Sales cycles getting shorter - Win rates improving - Customers arriving already convinced - Less selling required - Reputation doing the work Looking at the transcript: John Butler discusses the market opportunity and the potential for vadadustat. He mentions being first to market now (since roxadustat was not approved in the US), which is a change from expecting to be second. Dell Faulkingham discusses Auryxia growth: "Revenue for Auryxia continues to grow. We are encouraged with how the market views Auryxia’s strengths and applaud the commitment and tenacity of our team to find new ways to connect with customers and support patients." Dave Spellman: "For Auryxia net product revenue increased 7% to $36.8 million for the third quarter of 2021 compared with $34.4 million for the third quarter of 2020. The Akebia team is very proud of the performance, this is a challenging market where COVID has caused increased mortality in the patients we serve. The growth is reflective of a higher net revenue per pill than previously realized over the last three years and include some one-time true-ups that reflects what we believe is our current payer mix." So the Auryxia growth is attributed to higher net revenue per pill and one-time true-ups, not to easier winning of business. Regarding vadadustat, the company is preparing for launch but it's not yet approved. The discussion is about future potential, not current wins.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| NICE | NICE Ltd. | Q4 2023 | 2024-02-22 | B+ |
| ACGL | Arch Capital Group Ltd. | Q4 2023 | 2024-02-15 | B+ |
| VRNS | Varonis Systems, Inc. | Q2 2016 | 2016-08-09 | B+ |
| ACCO | ACCO Brands Corporation | Q1 2016 | 2016-04-27 | B+ |
ACCO · Q1 2016 → YESThe question is: Does management convey that IT HAS RECENTLY BECOME EASIER FOR THE COMPANY TO WIN BUSINESS THAN IT USED TO BE, based on real recent wins, and still in effect. YES The transcript shows management conveying that winning business has become easier than in the company's recent past. Boris Elisman states that customers have seen the value of the company's strong brands during the past couple of seasons, resulting in broader and deeper penetration in mass retailers and continued share gains.
NICE · Q4 2023 → YESThe question is: Does management convey that IT HAS RECENTLY BECOME EASIER FOR THE COMPANY TO WIN BUSINESS THAN IT USED TO BE, grounded in real business won recently, and still in effect.
VRNS · Q2 2016 → YESThe question is whether management conveys that it has recently become easier for the company to win business than it used to be, grounded in real recent wins, and still in effect.